PubAg

Main content area

Fibroblast growth factor 21 plays an inhibitory role in vascular calcification in vitro through OPG/RANKL system

Author:
Cao, Fangying, Liu, Xiaoxiao, Cao, Xiangrong, Wang, Shaoping, Fu, Kun, Zhao, Yejing, Shen, Fang, Liu, Jinghua
Source:
Biochemical and biophysical research communications 2017 v.491 pp. 578-586
ISSN:
0006-291X
Subject:
alkaline phosphatase, apoptosis, atherosclerosis, calcification, caspase-3, fibroblast growth factors, gene expression regulation, genes, ligands, metabolism, phosphatidylinositol 3-kinase, rats, smooth muscle, therapeutics, transcription (genetics), transcription factor NF-kappa B
Abstract:
Vascular calcification is prevalent and associated with adverse outcome without available therapy. The benefits of fibroblast growth factor (FGF)-21 on metabolism and atherosclerosis make it a promising therapeutic agent for vascular calcification. We investigated the effects of FGF21 on vascular smooth muscle cell (VSMC) calcification by culturing rat VSMCs in a calcifying medium for 9days. FGF21 markedly attenuated mineral deposition and apoptosis at the indicated time points. In the presence of FGF21, the expression levels of osteoblastic protein including bone morphogenic protein-2, alkaline phosphatase(ALP), runt-related transcription factor(RUNX)-2 and nuclear factor-kappa B ligand (RANKL) were down-regulated, whereas the expression of osteoprotegerin (OPG) increased. Knockdown of OPG significantly impaired inhibition of FGF21 on apoptosis and the expression of pro-apoptotic genes including caspase-3 and Bax and osteoblastic –promoting markers including ALP, RUNX-2 and RANKL. Furthermore, FGF21 facilitated the phosphoryl of AKT but suppressed P38, while OPG knockdown attenuated the effects. LY29400 (inhibitor of PI3K) abrogated the activation of PI3K/AKT and SB203580 (inhibitor of P38) abolished the inhibition of FGF21 on P38, while alteration was observed in the expression of RUNX-2. FGF21 inhibited VSMCs calcification via OPG/RANKL system, and through P38 andPI3K/AKT pathways.
Agid:
5827669